Corcept Therapeutics Inc (CORT)
51.33
+0.08
(+0.16%)
USD |
NASDAQ |
Jan 08, 12:53
Corcept Therapeutics SG&A Expense (Quarterly): 73.74M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| ADMA Biologics Inc | 18.56M |
| Catalyst Pharmaceuticals Inc | 45.88M |
| Madrigal Pharmaceuticals Inc | 107.58M |
| ACADIA Pharmaceuticals Inc | 133.29M |
| Ionis Pharmaceuticals Inc | 61.60M |